<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 71 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page70.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=71">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 71 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 71</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=71"><img src="../thumb/71.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>40 / 2020-04                                                         Central Nervous System - 1.6
   low. by 50 mg once dly.x2 wks. Thereaft.dos.may be incr. by max.50-  sens.occur.& discont.unless rash is clearly not med.-relat., do not re-  ers, outweigh benef.vs.risk if a woman becomes/plans pregn.dur.
   100 mg every 1-2 wks.until optim. respons.achiev./dose of 200 mg   start treatm. in asept.menigit.pts., lact.intol., adhere to recomm. dos.  ther.esp.1  trimest., monother.advis.dur.pregn., plasma lev. monit.
                                                                  st
   reached. Usual maint. dos.to achieve optim.respons: 100-200 mg/   esp.if valproate used concom., poss. dos. adjustm.reqd.when start./  recomm.& minim.effect.dos.advis.dur. pregn., poss.illn.aggravat.if
   day giv.once a day/in 2 div.dos.  stop.OC’s in pts. on maint.dos.not tak.induc.of lamotrigine glucuro-  anti-epilept.ther. interrupt.dur.pregn., folic acid. supplem.recomm.
   Childr. 2-12 yrs: Pts.not tak.sod.valproate: Init. 0,6 mg/kg bm/day   nidat., report change in menstr.pattern in pts. tak.OC’s, use appropr.  bef./dur.pregn., Vit.K 1 to be giv.to mothers dur.last pregn.wks.& to
   in 2 div.dos.x2 wks., follow.by 1,2 mg/kg/day x2 wks. Thereaft.the dos.  treatm.regim.with concom. lopinavir/ritonavir & atazanavir/ ritonavir  neonate, neonat.withdr.syndr., incr. relaps.risk dur.pregn. &/post-part.
   should be incr. by a max. 1,2 mg/kg every 1-2 wks.until optim. respons.  Interactions: Anti-epilept.agents which induc. hepat. drug metabol.  per.in women with bipol.disord., pass.into breast milk, not effect. in
   achiev. Usual maint.dos.to achieve optim. respons: 5-15 mg/kg/day in   enzymes signific.enhanc. metabol., sod.valproate signific.reduc.me-  absenc.& myoclon.seiz.
   2 div.dos. Max. dly. dos.of 400 mg not to be exceed.  tabol.& incr. plasma conc., being a weak inhibit.of dihydrofol. reduc-  Interactions: Horm.contracept.effic.affect., carbamazepine plasma
   Pts.tak.sod.valproate: Init: 0,15 mg/kg bm/day once dly x 2wks.  tase there is a possibil.of interfer.with folate metabol.dur.longt.ther.,   lev.rais.by: ibuprof./ danazol/ macrolide antibiot./desipramine/ fluox-
   follow.by 0,3 mg/kg/day once a day x2 wks. Thereaft.incr.dos by   incr. clear with concom.rifampic.,decr.conc.with lopinavir/ ritonavir   etine/ fluvoxamine/nefazodone/ paroxetine/ stiripentol/vigabatrin/
   max. 0,3 mg/kg every 1-2 wks.until optim.respons.achiev. Usual   & atazanavir/ritonavir, incr. plasma lev.of renal.excret.substrats.of   azole antifung./loratadine/ olanzapine/ isoniaz./acetazolamide/
   maint. dos: 1-5 mg/kg/day once dly.or in 2 div.dos. Max. dly.dos.of   OCT2 (e.g. metformin/ gabapentin/varenicline), poss.decr AUC with   diltiazem/ verapamil/ cimetid./omeprazole/oxybutynin/ dantrolene/
   200 mg not to be exceed.     chron.high paracetamol dos.   ticlopidine/& nicotinamide, carbamazepine-10,11-epoxide plasma
   Pts.tak.oxcarbazepine without any induc. /inhib. of lamotrigine   lev.rais.by loxapine/ quetiapine/primidone/progabide/ valproic acid/
   glucuronidat: Init: 0,3 mg/ kg bm/day once dly (or in 2 div.dos.) x   TEGRETOL, Novartis [P/S]  valnoctamide & valpromide, plasma lev.of carbamazepine and/or
   2wks. follow. by 0,6 mg/kg/day once a day (or in 2 div. dos.) x2 wks.   Carbamazepine  carbamazepine-10,11 metabolite decr.by felbamate/methsuximide/
   Thereaft.incr.dos by max.0,6 mg/kg every 1-2 wks.until optim.respons.  Indications: As mono- & combin.ther.in epilep. with motor & psych.  oxcarbazepine/ phenobarbitone/phensuximide/ phenytoin/ primi-
   achiev. /dose of 200 mg reached. Usual maint.dos: 1-10 mg/kg/day   manifest., psychomot.or temp. lobe, gen. ton.-clon.seiz., mix.forms,   done/clonazepam/cisplat./ doxorubicin/ rifampicin/theophyll./ami-
   once dly.or in 2 div.dos. Max.dly.dos.of 200 mg not to be exceed.   complex/ simple part. seiz.with/without loss of consciousn. with/   nophyll./ isotretinoin & St John’s wort, dimin.plasma lev./abolish
   Pts.aged 2-6 yrs. may require maint.dos.at high. end of scale.  without second.generalisat., ac.mania & maint. treatm.of bipol.af-  activ.of buprenorphine/methadone/ paracet./doxycycl./oral anti-
   Lennox-Gastaut Syndr: Dos.guidelines as above for adults &   fect.disords.to prev./ attent. recurr., idiopath.trigem.neuralg., idiopath.   coags./bupropion/ citalopram/mianserin, nefazodone/trazodone /
   childr.aged 2-12 yrs.        glosso-pharyng. neuralg.      TCA’s/aprepitant/clobazam/clonazepam/ ethosuximide/ felbamate/
   Bipolar.disord: Adults over 18 yrs: Do not exceed init.dos.& sub-  (S3) TABS, [P/S] B1530.  lamotrig./primidone/ tiagabine/topiramate/valproic acid/zonisamide/
   seq.escalat.dos. Follow. transit. regim.of dos.escalat.to maint.dos.  769398-007: 200 mg, 50, R228,85  itraconazole/ praziquantel/albendazole/imatinib/ cyclophosphamide/
   over 6 wks. to prev.recurr.of depress.episod. Other psychotrop. and/  (S3) CR TABS, [P/S] V/2.5/321,322.  lapatinib/temsirolimus/ clozapine/ haloperidol/bromperidol/quetia-
   or anti-epilept.drugs can then be withdr. if indicat. Consid.adjunct.  779652-002: 200 mg, 30, R145,86  pine/ risperidone/ ziprasidone/olanzapine/aripiprazole/ palperidone/
   ther.for prev.of man. episod.as effic.not conclus.est. If lamotrigine is   779660-005: 400 mg, 30, R269,80  alprazolam/theophylline/horm. contracept./ Ca chann.blocks./corti-
   to be terminat.no stepwise dos.reduct.is necess.  (S3) SUSP, [P/S] D/2.5/204. 100 mg/5 ml.  coster./ tadalafil/ ciclospor./everolim./tacrolim./sirolim., folic acid/
   Recomm.dos.escalat.in Bipol.disord: Adjunct. ther. with en-  769401-007: 250 ml, R221,21  mephenytoin lev.incr., phenytoin plasma lev. chang., poss.sympto-
   zyme inhibit. (eg.valproate): Init. 25 mg every alt.day x2 wks.follow.  Dosage: Tab.& susp.admin.dur./aft./betw.meals. CR Divitabs swall.  mat.hyponatraem.with some diuret., Tegretol-induc.toxic.incr.with
   by 25 mg once dly. x2 wks. Incr.dos.to 50 mg once dly/in 2 div. dos. in   unchew.with adeq.liq. & admin.in 2x dly dos.regim. Susp.produc.  levetiracetam, incr.isoniazid-induc.hepatotoxic., poss. incr.neurolog.
   wk.5. Usual target dos.is 100 mg/day admin once dly/in 2 div.dos.but   high.peak lev.at same tab. dos.theref.init.at low.dos.& incr.slow.   effs.with Li/metoclopramide/ haloperidol/ thioridazine, symptom.
   maybe incr.to max. 200 mg/day depend.on clinic.respons. Adjunct.  When switch.from tabs.to CR tabs.dos.may need to be incr. Grad.  hyponatream. with some diurets., eff.of non-depolaris.musc. relax.
                                       st
   ther.with enzyme induc. (eg.carbamazepine) in pts.NOT tak.  dos.reduct.of 1  anticonvuls.when switch. to Tegretol. Optim.therap.  antagon., alcoh.tol.reduc., CYP3A4 inhibit. incr. plasma conc.& CY-
   valproate: Init.50 mg once dly x 2 wks.follow.by 100 mg/day in 2   plasma lev. range 4-12 µg/ml.   P3A4 induc.decr.ser.lev.
   div.dos.x2 wks. Incr.to 200 mg/day admin.in 2 div. dos.in wk.5.& may   Epilep: Monother.if poss. Init.with low dly.dos.& incr.slow.unt.opt.eff.
   be incr.in wk.6 to 300 mg/ day. Usual target dos.is 400 mg/day in 2   achiev. Plasma lev.determin. poss.help in estab.optim.dos. Adults:   TOPALEX, (Sanofi-Aventis) Janssen-Cilag [P/S]
   div.dos. admin.from wk.7. Adjunct.ther.to drugs with no known   Init. 100-200 mg 1-2xdly incr. slow.to usual.400 mg 2-3xdly. 1 600 mg   Topiramate.
   clinic.interacts.(eg. Li/bupropion) OR as monother: Init.25 mg   dly in 3-4  div.dos.may be necess.  Indications: As monother.in new.diagn.epilep./ convers. to monoth-
   once dly.x2 wks.follow. by 50 mg once dly./in 2 div.dos.x2 wks.incr.  Childr: 4 yrs or less: Start.dos: 20-60 mg/day incr.by 20-60 mg   er.in pts.with epileps., adjunct. ther.in adults & childr.over 4 yrs.when
   to 100 mg /day in wk.5. Usual target dos.is 200 mg once dly/in 2 div.   every 2nd day. Over 4 yrs: Init. 100 mg/ day.incr.by 100 mg at wkly.  inadeq. contr.by convent.first line anti-epilept.meds.for partial onset
   Dos.range of 100-400 mg used in clinic. trails.  interv. Maint. dos: 10-20 mg/kg bm dly.in div.dos. Up to 1 yr: 100-  seiz.with/without second.gen.seiz., seiz. assoc.with Lennox-Gastaut
   Maint.stabilisat.tot.dly.dos.in Bipol.disord. follow. concom.  200 mg dly. 1-5 yrs: 200-400 mg dly. 6-10 yrs: 400-600 mg dly. 11-  syndr.& prim. generalis. tonic-clonic seiz.
   psychotrop./anti-epilept.drug withdr: Follow.withdr.of ad-  15 yrs: 600-1 000 mg dly.   (S3) TABS. 41/2.5/0622, 0623, 0624
   junct.enzyme inhibit. (e.g. valproate): Double stabilisat.dos.not   Trigem.neuralg: Init.200-400 mg dly.incr.grad. until freed.from pain   715978-001: 25 mg, 60, R205,38
   exceed.100 mg/wk.in wk.1 (i.e.100 mg/day will be incr.to 200 mg/day   achiev.normal.at 200 mg 3-4xdly, somet.1 600 mg dly. Reduc.grad.to   715979-001: 50 mg, 60, R377,58
   in wk.1). Maint.200 mg/day admin. in 2 div.dos.in wk.2 & 3 onwards.   low. maint. dos. Elderly & sensit.pts: Recomm.init. dos.100 mg 2xdly.  715981-001: 100 mg, 60, R671,20
   Follow. withdr.of adjunct.enzyme induc. (eg.carbamazepine)   Ac.mania & maint.treatm.of bipol.disords: Dos. range: Ap-  Dosage: Init.at low dos.titrat.to effect.dos. Tabs. not to be broken.
   depend.on origin.dos: Reduc. dos.grad.over 3 wks.as enzyme in-  prox.400-1 600 mg dly., usual dos. 400-600 mg dly.in 2-3 div.dos.   Monother: Discont.grad.at 1/3 of concomit.AED dos.every 2 wks.
   duc. withdr. If in wk.1: 400 mg then wk.2: 300 mg & wk.3: 200 mg. If   Ac.man: Incr.dos. rapid. Bipol.disord: Small dos.increm.recomm.in   recomm.unless safety concerns require abrupt withdr.
   in wk.1: 300 mg then wk.2: 225 mg & wk.3: 150 mg. If in wk.1: 200   maint.ther.to ensure optim.toler.  Adults: Init: 25 mg nightly x1 wk. incr.at 1-2 wkly. interv.by in-
   mg then wk.2: 150 mg & wk.3: 100 mg. Follow.withdr.of other   Contraindications: Hypersens.to structur.relat.drugs. eg. TCA’s, AV   crem.of 25-50 mg/day admin.in 2 div. dos. guid.by clinic.outcome.
   psychotrop./AED drugs with no known interacts. with lamo-  block, bone marr.depress./ porphyr.hist., concom.MAOI/within 2 wks.  Recomm.init. monother. target dos.is 100 mg/day. Max.recomm.
   trigine (e.g. Li/bupropion): Maint.target.dos.achiev.in dos.escalat.  of discont., lactat., prev.Stev.John.syndr.or tox.epiderm. necrolys.  dly. dos.500 mg/day.
   throughout withdr.of other med.  Side effects: V.common: dizzin., atax., drowsin., fatig., allerg.der-  Childr. 2 yrs and over: Init.0,5-1 mg/kg nightly x1 wk. incr. at
   Lamotrigine dly.dos.adjustm.in bipol.disord. follow. addit.of   matit., urticar., leukopen., N&V, incr.gamma-GT. Common: oed., fluit   1-2 wkly.interv.by increm.of 0,5-1 mg/ kg/ day admin.in 2 div.dos.
   other meds: Addit.of enzyme inhibit.(eg.valproate). With curr.  retent., weight incr.hyponatraem.& bld.osmolarity decr.due to ADH   guid.by clinic.outcome.
   stabilisat.dos. 200 mg/day: Wk.1: 100 mg/day which is to be maint.   like eff.rarely lead.to water intoxicat.& lethargy, vomit., headache,   Recomm.init.target dos.range is 100-400 mg/day. Dos of up to 500
   through wk.2 & wk.3 onwards. With curr. stabilisat.dos.300 mg/day:   confus.state, neurolog. disords., accomodat.disords., diplop., dry   mg/day in recent.diagnos.part. onset seiz.in childr.record.
   Wk.1: 150 mg/day which is to be maint.through wk.2 & wk.3 onwards.   mouth, incr. bld.alkal.phosphatase, thrombocytopen., eosinophil.   Adjunct.ther: Adults: Init: 25-50 mg nightly x1 wk. Subseq.at wkly.
   With curr.stabilisat.dos.400 mg/day: Wk.1: 200 mg/day which is to be   Uncommon: exfoliative dermatit., diarrh., constip., abnorm.invol.  interv.incr.by 25-50 mg/day admin.in 2 div. dos.guid.by clinic.outcome.
   maint.through wk. 2 & wk.3 onwards. Addit.of enzyme induc. (eg.  movem., nystagmus, incr. transaminas. Rare: jaund., hepatit., delay.   Usual tot.dly.dos: 200-400 mg in 2 div.dos. Max.dos: 800 mg/day.
   carbamazepine)when NOT tak.valproate. With curr.stabilisat.  multi-organ hypersens.disords., vanish.bile duct syndr., SLE, depress.,   Childr.4 yrs and over: Recomm.tot.dly.dos.is approx. 5-9 mg/kg/day
   dos.200 mg/day: Wk.1: 200 mg, in wk.2: 300 mg & in wk.3 onwards   leukocytos., lymphadenopathy, folic acid defic., hallucinat., anorex.,   in 2 div.dos. Init. 25 mg or less, based on range of 1-3 mg/kg/day at
   400 mg. With curr.stabilisat.dos.150 mg/day: Wk.1: 150 mg, in wk.2:   restlessn., aggress., agitat., orofac. dyskines., eye movem.& speech   night x1st wk. Incr.dos.at 1 or 2 wk.interv.by increm.of 1-3 mg/kg/day
   225 mg & in wk.3 onwards 300 mg. With curr. stabilisat.dos.100 mg/  disords., periph. neuropathy, card.conduct.disords., hyper-/hypotens.,   admin.in 2 div.dos.guid.by clinic. outcome.
   day: Wk.1: 100 mg, in wk.2: 150 mg & in wk.3 onwards 200 mg. Ad-  abdom.pain. V.rare: NMS, Stev.-John.syndr., anaphylact.react., an-  Contraindications: Safety & effic.in childr.und. 2 yrs.not est., safety
   dit.of other psychotrop./AED drugs with no known interacts.  gioed., AV-block with syncope, CHF, coron.arter.dis., thromboembol.,   in pregn.& lactat.not est.
   with lamotrigine (e.g. Li/bupropion): Maint.target.dos.achiev.in   interstit.nephrit., ren.fail., arthralg., musc.pain, asept.meningit., psy-  Side effects: Vis.disturbs.incl.ac.myopia assoc. with second.clos.
   dos. escalat.(200 mg/ day) with range of 100-400 mg.  chos. activat., agranulocytos., aplast.anaem., pancytopen., mega-  angl.glauc.even in paed.pts., metabol. acidos., CNS effs., memory
   Contraindications: Monother.in childr.und.12 yrs. not recomm.,   loblast.anaem., ac.intermitt./ variegate & cutanea tarda porphyr.,   impairm., decr./ incr.weight, fatig., bradyphren., abnorm. coordinat.,
   safety in pregn.& lactat.not est., hepat./ren.impairm., safety & effic.  reticulocytos. & haemolyt.anaem., incr.bld.prolactin with/without   paraesthes., GI effs.incl.GORD/ glossodyn./ gingiv. bleed., dysar-
   in childr.und.2 yrs.& pts.over 65 yrs not est.  clinic.manifestat., pancreatit., eye disords., pulm. hypersens., granu-  thr., speech disord., dysgeus., hypoaesthes., myalg., musc. spasm,
   Side effects: Freq: Irritabil., headache, drowsin., insomn., dizzin.,   lomatous hepatit., TEN, photosens., sex.dysfunct. Unknown: DRESS,   abnorm.gait., joint/fac.swell., bld.dyscras., ren./ urin.disords.incl.
   trem., paraesthes., nystagm., poor coordinat., diplop., blurr.vis., ver-  ac. gen. exanthema.pustulos (AGEP).  incontin., abnorm.skin odour, skin disords.incl.Stev.-John.syndr./tox.
   tigo, N&V, GI disords., diarrh., tiredn. Less freq: Infect., anaem.,   Warnings and special precautions: Pt. awaren. of early toxic.S&S   epiderm. necrolysis/erythema multiforme, alopec., tinnit., imp.hear.,
   neutropen., leucopen., thrombocytopen., pancytopen., aplast.anaem.,   of potent.haematolog. probl./ dermatol.or hepat.reacts., med.super-  dyspn., sex.dysfunct., card. disords., epistax., thirst, polydips., lym-
   agranulocytos., hypsersens. syndr., angioed., aggress., tics, halluci-  vis.essent. dur.ther., compl.pre-treatm.bld.counts & per. thereaft.,   phadenopath., vertigo, oed., influenza-like illn., nasopharyngit., psych.
   nat., confus., anx., depress., amnes., atax., agitat., unsteadin., Par-  monit.if low/decr.WBC/platel.count, discont. ther.if signif.bone marr.  disords.incl.mood disturbs., ren. fail., nephrolithias. with ren.colic, sui-
   kinson’s worsen., extrapyramid. effs., choreoathetos., incr.seiz.freq.,   depress./ hypersens. reacts./seiz.exacerbat., withdr.ther if S&S of sev.  cid.ideat. / attempts., hepatotoxic., hepatit.& hepat.fail.with concom.
   dysarthr., conjunctivit., chest pain, constip., dry mouth, dyspeps., incr.   skin.reacts.appear, (HLA)-A*3101 poss. risk fact.for developm.of ser.  multip.meds., hypersens.reacts., pyrex., asthen., vertigo, anhidros.
   LFT, hepat.dysfunct./fail., lupus-like reacts., asthen. Unknown freq:   cutan.adverse drug react., consid.test.for HLA-B* 1502 allele in pts.   Special precautions: Discont.ther.if syndr.of ac. myopia assoc.
   Disseminat. IV coagulat., red cell aplas., progress. immunosuppress.,   with ancestry in genet.at-risk populat.bef.init.ther., HLA-B*1502 al-  with second.clos.angl.glauc.occurs, contracept. effic.poss.decr.,
   vasculit., apnoea, rhinit., oesophagit., pancreatit., rhabdomyolys.,   lele test.of Han Chinese ancestry recomm.as strong Stev.John. & tox.   eval.ser.bicarbon.lev. dur. ther.& reduce/discont.if necess., chron.
   multi-organ fail. Bipolar dis.also: Freq: Agitat., somnol., skin rash,   epiderm. necrolys.correlat.report., mix.seiz., per.liv./ren. funct.monit.,   metabol. acidos.reduc.growth rates in paed.pts.& leads to nephro-
   arthralg., back pain, pain. Less freq: Stev.-Johns.syndr., erythema   withdr.ther.if liv.funct.deterior., susp.not for fruct.intol.pts., skin reacts.,   lithias. incr.fract.risk, incr.adverse effs. with lamotrigine, pts.advis.to
   multiforme, petech., fev.    outweigh benef.vs.risk & monit.pts.with card./ren./hepat. damage/  report chang. bleed. patterns when tak.estrog.-contain. contracept.,
   Warnings and special precautions: Monit.for signs of depress.&/  reacts.to other meds./interrupt.Tegretol cours., latent psychos.activ.,   monit.Li-lev.with concom.use, concom. meds. predispos.to nephro-
   suic.ideat./behav.& init. appropr. treatm., sev.convuls.seiz.incl.status   elderly, monit.pts. with incr.IOP, monit.suicid.ideat./behav.signs &   lithias.incr.risk of ren.stone format., cross.placent.barrier in animals,
   epilept. may lead.to rhabdomyolys./multiorg. dysfunct. & dissemi-  cons.appropr.ther., breakthr.bleed.with OC’s, alt. contracept./mono-  poss.incr.teratogen.effs.risk with combin. anti-epilept. drugs, out-
   nat.intravasc.coagulat., close monit. of hepat./ren.& clott.paramet.,   ther.advis.in women of childbear. potent., tol., seiz.precip.with abrupt   weigh benef.-risk dur. pregn., pass.into breastmilk, poss.congenit.
   consid. withdr. if combinat.of unexplain.rash/fev./flu-like sympts./   withdr., change-over to new anti-epilept.meds.to be done und. cover   malformat. if used dur.pregn., grad.withdr., monit. recomm. if rapid
   drowsin.or worsen.of seiz.contr.dur.1st mnth. of treatm.exper., abrupt.  of suit.meds.if abrupt withdr.necess., concom. levetiracetam/non-de-  withdr.requir., ren./hepat.funct. impairm., adeq.hydrat.esp.prior/dur
   withdr.may provoke rebound seiz., grad.withdr., monit.childr.weight to   polaris.musc.relax., abstain from alcoh.dur.ther., safety in pregn.not   exerc.& expos. to warm temp., monit./appropr.treatm.in case of
   maint. therap.dos., eval.all pts.prompt.if rash./ manifestats.of hyper-  est., incr.malformat./developm.disord.risk in childr. of epilept.moth-  suic. ideat., avoid concom.CNS depress./alcoh., diab. contr. monit.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page70.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page66.html">66</a>&nbsp;&nbsp;&nbsp;<a href="page67.html">67</a>&nbsp;&nbsp;&nbsp;<a href="page68.html">68</a>&nbsp;&nbsp;&nbsp;<a href="page69.html">69</a>&nbsp;&nbsp;&nbsp;<a href="page70.html">70</a>&nbsp;&nbsp;&nbsp;<a href="page71.html">71</a>&nbsp;&nbsp;&nbsp;<a href="page72.html">72</a>&nbsp;&nbsp;&nbsp;<a href="page73.html">73</a>&nbsp;&nbsp;&nbsp;<a href="page74.html">74</a>&nbsp;&nbsp;&nbsp;<a href="page75.html">75</a>&nbsp;&nbsp;&nbsp;<a href="page76.html">76</a>
             </td>
             <td width="35%"><a href="page72.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page72.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
